The invention relates to the use of substituted benzamide derivatives of Formula I: Wherein: A1 and A2 are &mdashN or &mdashCH, so that if A1 is &mdashN, then A2 is &mdashCH and If A2 is &mdashN, then A1 is &mdashCH R is a hydrogen atom, or represents branched or unbranched &mdash(C1-C3)-alkyl, &mdash(C1-C3)-alkyl, wherein one, two or three hydrogen atoms may be substituted by a halogen or hydroxyl, &mdash(C1-C3)&mdashO&mdash(C1-C3), &mdash(C1-C3)&mdashO&mdash(C1-C3), wherein one, two or three hydrogen atoms may be substituted by a halogen, or R is a group wherein R3 and R4 both together or independently are halogen, hydroxyl, &mdash(C1-C3)alkyl, wherein one, two or three hydrogen atoms may be substituted by a halogen or hydroxyl, &mdashO&mdash(C1-C3)-alkyl, &mdashO&mdash(C1-C3)-alkyl, wherein one, two or three hydrogen atoms may be substituted by a halogen, &mdashO&mdash((C1-C3)&mdashO&mdash(C1-C3), &mdashO&mdash(C1-C3)&mdashO&mdash(C1-C3), wherein one, two or three hydrogen atoms may be substituted by a halogen R1 and R2 both together or independently are halogen, hydroxyl, &mdash(C1-C3)-alkyl, &mdash(C1-C3C)-alkyl, wherein one, two or three hydrogen atoms may be substituted by a halogen or hydroxyl, &mdashO&mdash(C1-C3)-alkyl, &mdashO&mdash(C1-C3)-alkyl, wherein one, two or three hydrogen atoms may be substituted by a halogen, &mdashO&mdash(C1-C3)&mdashO&mdash(C1-C3), -0-(C1C3)&mdashO&mdash(C1C3), wherein one, two or three hydrogen atoms may be substituted by a halogen, their pharmaceutically acceptable salts, isomers or mixtures thereof as in vitro selective MAO-B inhibitors. The substituted benzamide derivatives of Formula I, their pharmaceutically acceptable salts, isomers or mixtures thereof are useful for the manufacture of a medicament for prevention and treatment of acute and chronic neurological disorders, cognitive and neurodegenerative diseases, more precisely for the manufacture of a medicament for prevention and treatment of neurodegenerative disorder
